FDA Approves Guardant’s Guardant360 CDX Comprehensive Genomic Profile
The liquid-biopsy test is also a companion diagnostic for osimertinib, AstraZeneca’s drug for non-small cell lung cancer.
You may also be interested in...
Guardant wants to become “one-stop-shop” in the cancer care continuum with the launch of an early-stage colorectal cancer test and planned launch of a tissue-based test.
CEO sees Guardant360 CDx approval as "watershed moment" for liquid biopsy and plans more biopharma partnerships.
AstraZeneca used its robust Q2 update to express hopes that Phase III data from of its COVID-19 vaccine candidate this year could provide it with a regulatory pathway. It is also entering a mAb combination into the clinic as a promising approach against COVID-19.